✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
PF-04958242 is an investigational drug.
There have been 14 clinical trials for PF-04958242. The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Schizophrenia, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Biogen, Pfizer, and Yale University.
There are forty-three US patents protecting this investigational drug and four hundred and thirteen international patents.
Recent Clinical Trials for PF-04958242
|Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants||Biogen||Phase 1|
|A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)||Biogen||Phase 2|
|A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)||Biogen||Phase 2|
Top disease conditions for PF-04958242
Top clinical trial sponsors for PF-04958242
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PF-04958242||See Plans and Pricing||2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides||Pfizer Inc. (New York, NY)||See Plans and Pricing|
|PF-04958242||See Plans and Pricing||Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors||Pfizer Inc. (New York, NY)||See Plans and Pricing|
|PF-04958242||See Plans and Pricing||Imidazopyridazine compounds||Pfizer Inc. (New York, NY)||See Plans and Pricing|
|PF-04958242||See Plans and Pricing||N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides||Pfizer Inc. (New York, NY)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PF-04958242||Argentina||AR099997||2034-04-10||See Plans and Pricing|
|PF-04958242||Australia||AU2015245260||2034-04-10||See Plans and Pricing|
|PF-04958242||Canada||CA2944971||2034-04-10||See Plans and Pricing|
|PF-04958242||Chile||CL2016002510||2034-04-10||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|